1993 - Fellow of the American Association for the Advancement of Science (AAAS)
Alexandros Makriyannis mainly focuses on Cannabinoid, Cannabinoid receptor, Pharmacology, Endocannabinoid system and Receptor. Alexandros Makriyannis combines subjects such as Agonist, Antagonist, Cannabinoid receptor type 2, Stereochemistry and Anandamide with his study of Cannabinoid. His research in Cannabinoid receptor intersects with topics in Endocrinology and Inverse agonist.
His Pharmacology research includes elements of AM251, Rimonabant, Hippocampal formation, Cannabinoid Receptor Agonists and In vivo. His work is dedicated to discovering how Endocannabinoid system, Fatty acid amide hydrolase are connected with Neuroprotection and other disciplines. His Receptor research includes themes of Inflammation, Neurochemical, Endogeny and Central nervous system.
His primary areas of study are Cannabinoid, Cannabinoid receptor, Pharmacology, Stereochemistry and Endocannabinoid system. The Cannabinoid study combines topics in areas such as Agonist, Endocrinology, Antagonist and Cannabinoid receptor type 2. His Cannabinoid receptor research is multidisciplinary, incorporating elements of Neuroscience and Ligand.
His studies in Pharmacology integrate themes in fields like AM251, Cannabinoid receptor antagonist, Rimonabant, Inverse agonist and In vivo. His Stereochemistry study incorporates themes from Biological activity, Structure–activity relationship, Ring and Chemical synthesis. The various areas that Alexandros Makriyannis examines in his Endocannabinoid system study include Endogeny and Fatty acid amide hydrolase.
His scientific interests lie mostly in Pharmacology, Cannabinoid, Cannabinoid receptor, Endocannabinoid system and Receptor. His Pharmacology research is multidisciplinary, relying on both In vivo, Inverse agonist, Antagonist, Rimonabant and Nicotine. The concepts of his Cannabinoid study are interwoven with issues in Agonist and Antagonism.
His biological study spans a wide range of topics, including Neuropathic pain and Stereochemistry. His Cannabinoid receptor study combines topics in areas such as Endocrinology and Neuroscience. His study explores the link between Endocannabinoid system and topics such as Fatty acid amide hydrolase that cross with problems in Anandamide, URB597 and Neuroprotection.
Alexandros Makriyannis mainly investigates Pharmacology, Endocannabinoid system, Cannabinoid, Cannabinoid receptor and Rimonabant. His study in Pharmacology is interdisciplinary in nature, drawing from both Cannabinoid receptor type 1, Fatty acid amide hydrolase, Opioid and Cannabinoid receptor type 2. His research integrates issues of Endocrinology, Arachidonic acid and Linoleic acid in his study of Endocannabinoid system.
Alexandros Makriyannis is investigating Cannabinoid receptor as part of his Receptor and Agonist and Cannabinoid receptor study. Alexandros Makriyannis works mostly in the field of Receptor, limiting it down to concerns involving Signal transduction and, occasionally, HEK 293 cells. The study incorporates disciplines such as Cannabinoid receptor antagonist, Inverse agonist and Nicotine in addition to Rimonabant.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Identification and Functional Characterization of Brainstem Cannabinoid CB2 Receptors
Marja D. Van Sickle;Marnie Duncan;Philip J. Kingsley;Abdeslam Mouihate.
Functional role of high-affinity anandamide transport, as revealed by selective inhibition.
M. Beltramo;N. Stella;A. Calignano;S. Y. Lin.
CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids.
Mohab M. Ibrahim;Frank Porreca;Josephine Lai;Phillip J. Albrecht.
Proceedings of the National Academy of Sciences of the United States of America (2005)
Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS
Mohab M. Ibrahim;Hongfeng Deng;Alexander Zvonok;Debra A. Cockayne.
Proceedings of the National Academy of Sciences of the United States of America (2003)
Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists.
Ruoxi Lan;Qian Liu;Pusheng Fan;Sonyuan Lin.
Journal of Medicinal Chemistry (1999)
CB2 cannabinoid receptor-mediated peripheral antinociception.
T.Philip Malan;Mohab M. Ibrahim;Hongfeng Deng;Qian Liu.
Endocannabinoids control spasticity in a multiple sclerosis model
D Baker;G Pryce;J L Croxford;P Brown.
The FASEB Journal (2001)
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity
Joseph Tam;V. Kiran Vemuri;Jie Liu;Sándor Bátkai.
Journal of Clinical Investigation (2010)
Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis
Sándor Bátkai;Zoltán Járai;Jens A. Wagner;Sravan K. Goparaju.
Nature Medicine (2001)
Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630.
Ruth A Ross;Heather C Brockie;Lesley A Stevenson;Vicki L Murphy.
British Journal of Pharmacology (1999)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: